Fennec Pharmaceuticals (FENC) Net Cash Flow Growth (1y) (2011 - 2025)
Powered by 
Analysis
Fennec Pharmaceuticals (FENC) Net Cash Flow Growth (1y) (2011 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 47.11% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.60% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -100.75% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 149.49% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -104.22% |
| 10 | Fennec Pharmaceuticals | 432.85 Mn | 391.60 Mn | 17.15 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 208.44% |
| Sep 30, 2025 | 218.58% |
| Jun 30, 2025 | 51.17% |
| Mar 31, 2025 | -110.44% |
| Dec 31, 2024 | -1,673.10% |
| Sep 30, 2024 | -6.84% |
| Jun 30, 2024 | -136.89% |
| Mar 31, 2024 | 804.22% |
| Dec 31, 2023 | 114.55% |
| Sep 30, 2023 | -117.25% |
| Jun 30, 2023 | -2.63% |
| Mar 31, 2023 | -89.51% |
| Dec 31, 2022 | -84.79% |
| Sep 30, 2022 | 601.59% |
| Jun 30, 2022 | 24.45% |
| Mar 31, 2022 | 20.93% |
| Dec 31, 2021 | -14.64% |
| Sep 30, 2021 | 46.83% |
| Jun 30, 2021 | -115.35% |
| Mar 31, 2021 | 4.16% |